DigiSight Technologies, Inc. – Trademark Portfolio
Entity Type: 03
DigiSight Technologies, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VERANA HEALTH. The owner is based in San Francisco, CA.
156 Second Street, Suite 611
San Francisco, CA 94105
Showing of trademarks Trademarks
Trademark Classifications
DigiSight Technologies, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does DigiSight Technologies, Inc. have?
DigiSight Technologies, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned, 2 cancelled.
What trademark classes does DigiSight Technologies, Inc. file in?
DigiSight Technologies, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are DigiSight Technologies, Inc.'s most well-known trademarks?
DigiSight Technologies, Inc.'s registered trademark portfolio includes well-known marks such as VERANA HEALTH. These are among 1 currently registered trademark in the portfolio.
What is DigiSight Technologies, Inc.'s trademark registration success rate?
DigiSight Technologies, Inc. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.